Treatment of NonHodgkin's lymphomas with rituximab in Slovene patients

Medical Oncology

Volumn 27, Issue 2, 2010, Pages 167-176

  Novaković, Barbara Jezeršek ^a   Benigar, Ana ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

NonHodgkin's lymphomas; Rituximab; Treatment

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRITUMOMAB TIUXETAN; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE; MONOCLONAL ANTIBODY;

ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MONOTHERAPY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SLOVENIA; TREATMENT RESPONSE; COMPARATIVE STUDY; MORTALITY; SURVIVAL RATE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; HUMANS; LYMPHOMA, NON-HODGKIN; SLOVENIA; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77956932222     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9188-x     Document Type: Article

References (19)

1. Canellos GP, Lister TA, Sklar JL, editors. The lymphomas. 2nd ed. Philadelphia: W.B. Saunders Company; 2006.
2. Primic Z ̌ akelj M, Bračko M, Hočevar M, Pompe-Kirn V, Strojan P, Zadnik V, et al., editors. Cancer incidence in Slovenia 2004. Ljubljana: Institute of Oncology, Cancer registry of Slovenia; 2007.
3. Molina A. A decade of rituximab: improving survival outcomes in Non-Hodgkin's lymphoma. Annu Rev Med. 2008;59:237-50. doi:10.1146/annurev.med. 59.060906.220345. (Pubitemid 351291630)
4. Lucas BJ, Horning SJ. Monoclonal antibodies have finally arrived. In: Cavalli F, Armitage JO, Longo DL, editors. Annual of lymphoid malignancies. London: Martin Dunitz Ltd; 2001. p. 153-67.
5. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene. 2005;24:2121-43. doi:10.1038/sj.onc.1208349. (Pubitemid 40516580)
6. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDECC2B8) in patients with recurrent B-cell lymphoma. Blood.1994;84:2457-66.
7. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann of Oncol. 2003;14:520-35. doi:10.1093/annonc/mdg175. (Pubitemid 41295078)
8. Maloney DG. Mechanisms of action of rituximab. Anticancer Drugs. 2001;12(Suppl 2):1-4. doi:10.1097/00001813-200101000-00001. (Pubitemid 32142277)
9. Cvetkovic RS, Perry CM. Rituximab: a review of its use in non- Hodgkin's lymphoma and chronic lymphocytic leukemia. Drugs. 2006;66:791-820. doi:10.2165/00003495-200666060-00005. (Pubitemid 43778729)
10. National Comprehensive Cancer Network, Inc. NCCN clinical practice guidelines in oncology-Version 1.2007. Non-Hodgkin's lymphomas. http://www.nccn.org/professionals/physician.gls/PDF/nhl.pdf.
11. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105: 1417-23. doi:10.1182/blood-2004- 08-3175. (Pubitemid 40223656)
12. Foussard C, Mounier N, Van Hoof A. Update of the FL2000 randomized trial combining rituximab to CHVP-interferon in follicular lymphoma patients. J Clin Oncol ASCO Annu Meet Proc. 2006;24:7508. (Abstr).
13. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group. Blood. 2005;106: 3725-32. doi:10.1182/blood- 2005-01-0016. (Pubitemid 41742196)
14. Herold M, Haas A, Srock S, Neser S, Al-Ali KH, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German study group hematology and oncology study. J Clin Oncol. 2007;25:1986-92. doi:10.1200/JCO.2006.06.4618. (Pubitemid 46972781)
15. Van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295-301. doi:10.1182/blood-2006-05-021113. (Pubitemid 44794222)
16. Forstpointner R, Unterhalt M, Dreyling M, Böck HP, Repp R, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood. 2006;108:4003-8. doi:10.1182/blood-2006-04-016725. (Pubitemid 44920177)
17. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23:4117-26. doi:10.1200/JCO.2005.09.131. (Pubitemid 46211317)
18. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121-7. doi:10.1200/JCO.2005.05.1003. (Pubitemid 46638950)
19. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, et al. CHOP-like chemotherapy plus rituximab versus CHOPlike chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera international trial (MInT) group. Lancet Oncol.2006;7:379-91. doi:10.1016/S1470-2045(06)70664-7.